Technology developed by CSIRO Livestock Industries (CLI) will lead to the development of strategies designed to substantially reduce the $140 million lost each year due to Australian dairy cows contracting udder infections.

Melbourne's St Vincent's Institute of Medical Research has opened its new AUD$10.5 million medical research building on the St Vincent's Hospital campus. [ + ]

The first NSW biotechnology listing of 2004 is on the launch pad. Rather than listing in an IPO, Sydney-based BioSignal has chosen to make its debut via the back door, using as its vehicle Perth-based CTI Communications, which yesterday raised $4 million in an oversubscribed share issue and will acquire 100 percent of BioSignal’s shares. [ + ]

Bresagen's administrators have reached an in-principle agreement with Queensland-based public unlisted biotech company CBio for the restructure and relisting of the company. [ + ]

If Queensland Premier Peter Beattie fulfils his ambition of appropriating Victoria’s mantle as the Biotech State, he will be indebted to itinerant Brisbane resident Chuck Feeney. [ + ]

Having secured patent coverage for its vaccine technology, London-based Onyvax will extend its collaboration with researchers from the Queensland University of Technology and the Princess Alexandra Hospital. [ + ]

Novogen (ASX: NRT) has announced updated results from two clinical trials of its anti-cancer drug phenoxodiol, which is being developed by the company's US-based subsidiary Marshall Edwards (LSE AIM: MSH; Nasdaq: MSHL). [ + ]

Adelaide biotech Bionomics’ (ASX:BNO, OTC:BMICY) successful share placement last month has raised nearly $4 million of the $6 million needed to fast-track its epilepsy and anxiety-drug discovery program, while causing minimal angst among shareholders. [ + ]

Eiffel Technologies (ASX : EIF) announced today it has completed further animal studies in its development of improved injectable insulin, and would focus resources on collaborations with pharmaceutical companies working on inhaled or transdermal insulin. [ + ]

Minimising the side-effects that plague patients taking opioid pain-relievers will be the big advantage of Queensland-based QRxPharma’s novel opioid candidate Q8003, according to Alex Baker, Program Manager at QRxPharma. [ + ]

Australian scientists believe it may be possible to grow replacement organs organically, by providing organ-building stem cells with a 3-D template and leaving them to grow in situ, within the patient’s own body. [ + ]

Former Perth-based telecommunications company Southpointe (ASX: SOU) plans to become a biotechnology investment company after acquiring interests in two biotechnology-related ventures. [ + ]

VRI Biomedical has announced plans to raise up to AUD$2.9 million through a just completed share placement and a non-renounceable rights issue to be put towards production and marketing of the company's proTract probiotic products. [ + ]

CSIRO, the Australian Institute for Marine Science, and other publicly funded research agencies (PRFAs) may be in for a funding shake-up, following the release of the Research Collaboration Review by Federal Minister for Education, Science and Training Brendan Nelson last week. [ + ]

Gradipore (ASX: GDP) has changed its name to Life Therapeutics to reflect its new strategy, the company announced today. [ + ]